Walleye Capital LLC Has $9.30 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

Walleye Capital LLC cut its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 34.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 212,656 shares of the company's stock after selling 111,076 shares during the period. Walleye Capital LLC owned 0.13% of Revolution Medicines worth $9,302,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc bought a new stake in Revolution Medicines during the 4th quarter worth about $34,000. Sterling Capital Management LLC grew its stake in shares of Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after purchasing an additional 1,613 shares in the last quarter. Daiwa Securities Group Inc. raised its position in Revolution Medicines by 521.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after purchasing an additional 3,178 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in Revolution Medicines during the 4th quarter worth $173,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Revolution Medicines news, insider Mark A. Goldsmith sold 11,738 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares of the company's stock, valued at $17,238,658.56. This represents a 2.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Margaret A. Horn sold 3,058 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the sale, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This trade represents a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is owned by corporate insiders.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $0.56 on Friday, hitting $36.76. The company had a trading volume of 1,274,876 shares, compared to its average volume of 1,423,603. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The stock has a 50-day moving average of $37.79 and a 200-day moving average of $44.42. The firm has a market capitalization of $6.83 billion, a P/E ratio of -10.24 and a beta of 1.37.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). Equities analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus dropped their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. HC Wainwright raised their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Wedbush reissued an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, February 27th. UBS Group lifted their price objective on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $59.00 target price on shares of Revolution Medicines in a research note on Tuesday, April 8th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $66.67.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.